N. prodotti: 0
Totale ordine: € 0,00
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,118
Online ISSN 1827-1634
Mustafa OZBEK 1, Askin GUNGUNES 1, Mustafa SAHIN 2, Zeynep GINIS 3, Bekir UCAN 1, Muyesser SAYKI 1, Esra TUTAL 1, Erman CAKAL 1, Şerife M. KUŞKONMAZ 4, Mehmet A. ÖZTÜRK 5, Tuncay DELIBASI 1
1 Department of Endocrinology and Metabolism, Diskapi Teaching and Research Hospital, Ankara, Turkey; 2 Department of Endocrinology and Metabolism, Ankara University School of Medicine, Ankara, Turkey; 3 Department of Biochemistry, Diskapi Teaching and Research Hospital, Ankara, Turkey; 4 Department of Endocrinology and Metabolism, Gazi University Faculty of Medicine, Ankara Turkey; 5 Department of Rheumatology, Gazi University Faculty of Medicine, Ankara, Turkey
BACKGROUND: Heart type fatty acid binding protein (H-FABP) is a small protein and released into the circulation when myocardial damage has occurred. Previous studies have demonstrated that H-FABP is closely associated with cardiac and some endocrinologic disorders including prediabetes, metabolic syndrome, and acromegaly. Hyperthyroism is a well-known disorder associated with cardiovascular diseases. We aimed to investigate the effect of hyperthyrodism on H-FABP levels.
METHODS: Forty six patients with hyperthyroidism with no known history of coronary artery disease and 40 healthy controls are involved in the study. Serum H-FABP levels are measured using sandwich enzyme-linked immunosorbent assay.
RESULTS: There was no significant difference between serum H-FABP levels of patients with hyperthyroidism and controls (871±66 pg/mL, and 816±66 pg/mL, respectively P=0.56). There was no significant correlation between H-FABP, free triiodothyronine (fT3), free thyroxine (fT4), and thyroid stimulating hormone (TSH) levels in patients and controls.
CONCLUSIONS: Serum H-FABP levels are not altered in patients with hyperthyroidism.